Literature DB >> 17641038

Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses.

Karin Loré1, William C Adams, Menzo J E Havenga, Melissa L Precopio, Lennart Holterman, Jaap Goudsmit, Richard A Koup.   

Abstract

Although replication-incompetent recombinant adenovirus (rAd) type 5 is a potent vaccine vector for stimulating T and B cell responses, high seroprevalence of adenovirus type 5 (Ad5) within human populations may limit its clinical utility. Therefore, alternative adenovirus serotypes have been studied as vaccine vectors. In this study, we characterized the ability of rAd5 and rAd35 to infect and induce maturation of human CD11c(+) myeloid dendritic cells (MDCs) and CD123(+) plasmacytoid dendritic cells (PDCs), and their ability to stimulate Ag-specific T cells. Both MDCs and PDCs were found to express the primary receptor for Ad35 (CD46) but not Ad5 (coxsackie-adenovirus receptor; CAR). Both dendritic cell (DC) subsets were also more susceptible to rAd35 than to rAd5. MDCs were more susceptible to both rAd35 and rAd5 than were PDCs. Whereas rAd35 used CD46 for entry into DCs, entry of rAd5 may be through a CAR-independent pathway. Exposure to rAd35 but not rAd5 induced high levels of IFN-alpha in PDCs and phenotypic differentiation in both DC subsets. MDCs and PDCs exposed to either rAd5 or rAd35 encoding for CMV pp65 were able to present pp65 and activate CMV-specific memory CD8(+) and CD4(+) T cells in a dose-dependent manner, but MDCs stimulated the highest frequencies of pp65-specific T cells. Responding T cells expressed multiple functions including degranulation (CD107a surface mobilization) and production of IFN-gamma, IL-2, TNF-alpha, and MIP-1beta. Thus, the ability of rAd35 to naturally target important DC subsets, induce their maturation, and appropriately present Ag to T cells may herald greater in vivo immunogenicity than has been observed with rAd5.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17641038      PMCID: PMC2365753          DOI: 10.4049/jimmunol.179.3.1721

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

1.  Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells.

Authors:  D Rea; M J Havenga; M van Den Assem; R P Sutmuller; A Lemckert; R C Hoeben; A Bout; C J Melief; R Offringa
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

Review 2.  Viral vectors for dendritic cell-based immunotherapy.

Authors:  L Jenne; G Schuler; A Steinkasserer
Journal:  Trends Immunol       Date:  2001-02       Impact factor: 16.687

3.  Adenovirus vector-induced inflammation: capsid-dependent induction of the C-C chemokine RANTES requires NF-kappa B.

Authors:  Gloria P Bowen; Stephanie L Borgland; Mindy Lam; Towia A Libermann; Norman C W Wong; Daniel A Muruve
Journal:  Hum Gene Ther       Date:  2002-02-10       Impact factor: 5.695

4.  Improved adenovirus vectors for infection of cardiovascular tissues.

Authors:  M J Havenga; A A Lemckert; J M Grimbergen; R Vogels; L G Huisman; D Valerio; A Bout; P H Quax
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Downregulation of human CD46 by adenovirus serotype 35 vectors.

Authors:  F Sakurai; K Akitomo; K Kawabata; T Hayakawa; H Mizuguchi
Journal:  Gene Ther       Date:  2007-03-22       Impact factor: 5.250

6.  Reciprocal regulation of plasmacytoid dendritic cells and monocytes during viral infection.

Authors:  W Zou; J Borvak; S Wei; T Isaeva; D T Curiel; T J Curiel
Journal:  Eur J Immunol       Date:  2001-12       Impact factor: 5.532

7.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

8.  Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset.

Authors:  D Rea; F H Schagen; R C Hoeben; M Mehtali; M J Havenga; R E Toes; C J Melief; R Offringa
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

9.  Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells.

Authors:  Jennifer Lund; Ayuko Sato; Shizuo Akira; Ruslan Medzhitov; Akiko Iwasaki
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307

10.  Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake.

Authors:  Oliver Meier; Karin Boucke; Silvija Vig Hammer; Stephan Keller; Robert P Stidwill; Silvio Hemmi; Urs F Greber
Journal:  J Cell Biol       Date:  2002-09-09       Impact factor: 10.539

View more
  49 in total

Review 1.  Novel adenovirus vector-based vaccines for HIV-1.

Authors:  Dan H Barouch
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

2.  Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN.

Authors:  William C Adams; Emily Bond; Menzo J E Havenga; Lennart Holterman; Jaap Goudsmit; Gunilla B Karlsson Hedestam; Richard A Koup; Karin Loré
Journal:  J Gen Virol       Date:  2009-03-12       Impact factor: 3.891

3.  Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

Authors:  Kylie M Quinn; Daniel E Zak; Andreia Costa; Ayako Yamamoto; Kathrin Kastenmuller; Brenna J Hill; Geoffrey M Lynn; Patricia A Darrah; Ross W B Lindsay; Lingshu Wang; Cheng Cheng; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Emma Gostick; David A Price; Jason G D Gall; Mario Roederer; Alan Aderem; Robert A Seder
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

Review 4.  Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development.

Authors:  E G Rhee; D H Barouch
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

5.  Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.

Authors:  Patricia A Darrah; Diane L Bolton; Andrew A Lackner; Deepak Kaushal; Pyone Pyone Aye; Smriti Mehra; James L Blanchard; Peter J Didier; Chad J Roy; Srinivas S Rao; David A Hokey; Charles A Scanga; Donata R Sizemore; Jerald C Sadoff; Mario Roederer; Robert A Seder
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

6.  Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.

Authors:  L Jean Patterson; Seraphin Kuate; Mara Daltabuit-Test; Qingsheng Li; Peng Xiao; Katherine McKinnon; Janet DiPasquale; Anthony Cristillo; David Venzon; Ashley Haase; Marjorie Robert-Guroff
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

7.  Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS.

Authors:  Monica Vaccari; Rabih Halwani; L Jean Patterson; Adriano Boasso; Jennifer Beal; Elzbieta Tryniszewska; Anna Hryniewicz; David Venzon; Elias K Haddad; Mohamed El-Far; Margherita Rosati; George N Pavlakis; Barbara K Felber; Saleh Al-Muhsen; Marjorie Robert-Guroff; Rafick-Pierre Sekaly; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

8.  Robust, vaccine-induced CD8(+) T lymphocyte response against an out-of-frame epitope.

Authors:  Nicholas J Maness; Nancy A Wilson; Jason S Reed; Shari M Piaskowski; Jonah B Sacha; Andrew D Walsh; Elizabeth Thoryk; Gwendolyn J Heidecker; Michael P Citron; Xiaoping Liang; Andrew J Bett; Danilo R Casimiro; David I Watkins
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

9.  Primary human immunodeficiency virus type 1-specific CD8+ T-cell responses induced by myeloid dendritic cells.

Authors:  Bonnie A Colleton; Xiao-Li Huang; Nada M Melhem; Zheng Fan; Luann Borowski; Giovanna Rappocciolo; Charles R Rinaldo
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

Review 10.  The influence of innate and pre-existing immunity on adenovirus therapy.

Authors:  Anne K Zaiss; Hidevaldo B Machado; Harvey R Herschman
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.